Bioavailability of fluorescein from a new drug delivery system in human eyes

British Journal of Ophthalmology

Volumn 88, Issue 1, 2004, Pages 48-53

  Steinfeld, A ^a   Lux, A ^a   Maier, S ^b   Suverkrup R ^b   Diestelhorst, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; FLUORESCEIN;

ADULT; ANTERIOR EYE CHAMBER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; EYE; FEMALE; FLUOROPHOTOMETRY; HUMAN; INTERMETHOD COMPARISON; LYOPHILISATE; MALE; NORMAL HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTERIOR CHAMBER; BIOLOGICAL AVAILABILITY; CORNEA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EYE; FEMALE; FLUORESCEIN; FLUOROPHOTOMETRY; FREEZE DRYING; HUMANS; MALE; OPHTHALMIC SOLUTIONS;

EID: 0347755361     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.88.1.48     Document Type: Article

References (27)

1. Dinslage S, Diestelhorst M, Weichselbaum A, et al. Lyophilisates for drug delivery in ophthalmology: pharmacokinetics of fluorescein in the human anterior segment. Br J Ophthalmol 2002;86:10-13.
2. Le Bourlais C, Acar L, Zia H, et al. Ophthalmic drug delivery systems - recent advances. Prog Ret Eye Res 1998;17:33-58.
3. Brown MM, Brown GC, Spaeth GL. Improper topical self-administration of ocular medication among patients with glaucoma. Can J Ophthalmol 1984;19:1-6.
4. DeSantis LM, Patil PN Pharmacokinetics. In: Havener WH, ed. Ocular pharmacology, 6th ed. St Louis: Mosby, 1994:22-45.
5. Fraunfelder FT. Drugs used primarly in ophthamolgy. In: Drug-induced ocular side effects, 4th ed. Baltimore: William & Wilkins, 1996:420-43.
6. Sugrue MF. The pharmacology of antiglaucomatous drugs. Pharm Ther 1989;43:91-138.
7. Furrer P, Mayer J, Gurny R. Ocular tolerance of preservatives and alternatives, Eur J Pharm Biopharm 2002;53:263-80.
8. Olson R, White G. Preservatives in ophthalmic topical medications: a significant cause of disease. Cornea 1990;9:363-4.
9. Alani SD. The ophthalmic rod: a new ophthalmic drug delivery system. Graefes Arch Clin Exp Ophthalmol 1990;228:297-301.
10. Diestelhorst M, Krieglstein GK. The ocular tolerability of a new ophthalmic drug delivery system (NODS). Int Ophthalmol 1994;18:1-4.
11. Shell JW. Ophthalmic drug delivery systems. Drug Dev Res 1985;6:245-61.
12. Diestelhorst M, Grunthal S, Süverkrüp R. Dry drops: a new preservative-free drug delivery system. Graefes Arch Clin Exp Ophthalmol 1999;237:394-8.
13. McLaren JW, Brubaker RF. A two-dimensional scanning ocular fluorophotometer. Invest Ophthalmol Vis Sci 1985;26:144.
14. Munnerlyn CR, Gray JR, Hennings DR. Design considerations for a fluorophotometer for ocular research. Graefes Arch Clin Exp Ophthalmol 1985;222:209.
15. Mosier MA, Gray JR, Ishimoto BM. Ocular fluorophotometer analysis. Curr Eye Res 1983;2:699.
16. Lux A, Diestelhorst M, Sueverkruep R. Comparative bioavailability study of identical doses of fluorescein: three eye drops v a single lyophilisate: Br J Ophthalmol, (in press).
17. Patton TF, Franceur M. Ocular bioavailability and systemic loss of topically applied ophthalmic drugs. Am J Ophthalmol 1978;85:225-9.
18. Patton TF, Robinson JR. Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes. J Pharm Sci 1976;65:1295-301.
19. Wood R, Li V, Robinson JR. Ocular disposition of poly-hexyl-2.cyano[3-14] acrylate nanoparticles in the albino rabbit. Int J Pharm 1985;23:175-83.
20. Lee VHL, Robinson JR. Mechanistic and quantitative evaluation of precornal pilocarpine disposition in albino rabbits. J Pharm Sci 1979;68:673-84.
21. Van Beek LM, de Keizer RJ, Polak BC, et al. Incidence of ocular side effects of topical β blockers in the Netherlands. Br J Ophthalmol 2000;84:856-9.
22. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol 1980;25:15-30.
23. Gasset AR, Ishii Y, Kaufmann HE, et al. Cytotoxity of ophthalmic preservatives. Am J Ophthalmol 1974;78:98-105.
24. Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjuntival surface. Curr Eye Res 1998;17:419-25.
25. Lemp MA, Zimmermann LE. Toxic endothelial degeneration in ocular surface disease treated with topical medications containing benzalkonium chloride. Am J Ophthalmol 1988;105:670-3.
26. Marquant R, Schubert T. Beeinflussung der Traenenfilmaufreisszeit (BUT) durch Betablocker-Augentropfen ohne Konservierungstropfen. Klin Monatsbl Augenheilkd 1991;199:75-8.
27. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-23.